News Archives

News Archives

Avivagen Secures First Order of OxC-beta™ Livestock in Malaysia

Ottawa, ON / Business Wire / December 12, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it has secured its first order for the use of OxC-beta™ Livestock in Malaysia. The 100-kilogram order quickly follows the recent approval of OxC-beta™ Livestock for use in feed for broilers and swine in the …Read More

Avivagen Receives Approval for Use of OxC-beta™ Livestock in Malaysia

Ottawa, ON / Business Wire / December 5, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it has received approval for the use of OxC-beta™ Livestock in Broilers  and Swine in Malaysia. With the addition of Malaysia,  OxC-betaTM Livestock is now approved for use in eight markets worldwide, including the United …Read More

Avivagen Attends 5th Annual Torrey Hills Capital Emerging Growth Conference in Rancho Santa Fe, California

Ottawa, ON, November 22, 2019: – Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it presented at the 5th Annual Torrey Hills Capital Emerging Growth Conference on November 21, 2019. The conference, which is by invitation only, was the first time Avivagen presented to a U.S. West Coast investor audience. Kym Anthony, CEO, and …Read More

Avivagen Secures Third Major OxC-beta™ Livestock Order in Asia-Pacific

UNAHCO seeks to expand use of OxC-BetaTM Livestock with new application in Broilers, creating new market opportunity for expanded use in a wide variety of feeds worldwide Ottawa, ON/ Business Wire/ November 12, 2019: – Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it has secured another substantial order for 2.1 metric tons of …Read More

Avivagen Share Issue

Ottawa, ON /Business Wire/ November 11, 2019 / Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, announces that it will issue 80,645  common shares pursuant to a previously …Read More

Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants

Ottawa, ON / Business Wire/ October 23, 2019/ – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, announces that it has received approval by the TSX Venture Exchange to …Read More